Polyrizon Secures US Patent Application for T&T Mucoadhesive Nasal Delivery Platform
PLRZ•Polyrizon’s US2024/0358741 A1 patent application for its Trap & Target™ mucoadhesive polymer platform for nasal drug delivery was published on June 17, 2026. The biocompatible composition combines sulfated polysaccharides and hydrophilic polymers, aiming to enhance nasal formulation retention, bioavailability, sprayability and film formation for vaccines, biologics and other APIs.
1. Patent Publication Details
On June 17, 2026, Polyrizon’s US patent application US2024/0358741 A1 titled “Mucoadhesive Polymers for Nasal Drug Delivery” was published, marking a key milestone in securing intellectual property for its Trap & Target™ (T&T) mucoadhesive platform.
2. Trap & Target™ Platform Technology
The Trap & Target™ platform leverages sulfated polysaccharides and hydrophilic polymers partially crosslinked with divalent ions to form durable films on nasal mucosa. This composition is designed to increase viscosity, sprayability and adhesion, potentially improving retention and absorption of intranasal formulations.
3. Potential Applications and Impact
The platform could support sprays, gels, inhalation products and systemic delivery of anti-inflammatory drugs, vaccines, biologics and other APIs. Publication of the application strengthens Polyrizon’s IP portfolio and could accelerate partnerships or licensing discussions as the technology advances toward clinical development.
